Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Most frequent adverse events and serious adverse events during the extension phase (extension safety population)

From: Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

Adverse event, n (%) Placebo-fingolimod 0.5 mg (n = 27) Placebo-fingolimod 1.25 mga(n = 23) Continuous fingolimod 0.5 mg (n = 47) Continuous fingolimod 1.25 mga(n = 46)
Any adverse event 22 (81.5) 23 (100) 35 (74.5) 41 (89.1)
Any serious adverse event 1 (3.7) 4 (17.4) 1 (2.1) 0 (0.0)
Any adverse event leading to discontinuation of study drug 5 (18.5) 3 (13.0) 2 (4.3) 0 (0.0)
Any infection or infestation adverse event 11 (40.7) 14 (60.9) 23 (48.9) 28 (60.9)
Most commonly reported adverse events b
 Nasopharyngitis 7 (25.9) 7 (30.4) 16 (34.0) 19 (41.3)
 Liver function test abnormal 4 (14.8) 9 (39.1) 3 (6.4) 4 (8.7)
 Leukopenia 4 (14.8) 1 (4.3) 0 (0.0) 3 (6.5)
 Bradycardia 0 (0.0) 3 (13.0) 0 (0.0) 0 (0.0)
 Influenza 0 (0.0) 3 (13.0) 0 (0.0) 2 (4.3)
 Second-degree atrioventricular block 0 (0.0) 3 (13.0) 0 (0.0) 0 (0.0)
 Headache 0 (0.0) 2 (8.7) 5 (10.6) 0 (0.0)
 Lymphocyte count decreased 1 (3.7) 2 (8.7) 1 (2.1) 2 (4.3)
 Lymphopenia 0 (0.0) 2 (8.7) 0 (0.0) 3 (6.5)
 γ-glutamyltransferase increased 1 (3.7) 2 (8.7) 1 (2.1) 0 (0.0)
 White blood cell count decreased 0 (0.0) 2 (8.7) 0 (0.0) 1 (2.2)
 Eczema 0 (0.0) 1 (4.3) 1 (2.1) 4 (8.7)
 Rash 2 (7.4) 1 (4.3) 1 (2.1) 0 (0.0)
 Alanine aminotransferase increased 2 (7.4) 0 (0.0) 0 (0.0) 0 (0.0)
 Blood triglycerides increased 2 (7.4) 0 (0.0) 0 (0.0) 0 (0.0)
 Dental caries 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.5)
 Diarrhea 1 (3.7) 0 (0.0) 2 (4.3) 3 (6.5)
 Stomatitis 1 (3.7) 1 (4.3) 0 (0.0) 3 (6.5)
 Pharyngitis 0 (0.0) 1 (4.3) 1 (2.1) 3 (6.5)
 Tinea pedis 1 (3.7) 1 (4.3) 3 (6.4) 0 (0.0)
 Skin papilloma 0 (0.0) 0 (0.0) 3 (6.4) 0 (0.0)
Serious adverse events     
 Bradycardia 0 (0.0) 2 (8.7) 0 (0.0) 0 (0.0)
 Leukoencephalopathyc 0 (0.0) 1 (4.3) 0 (0.0) 0 (0.0)
 Multiple sclerosis relapse 0 (0.0) 0 (0.0) 1 (2.1) 0 (0.0)
 Neuromyelitis optica 1 (3.7) 0 (0.0) 0 (0.0) 0 (0.0)
 Abortion induced 0 (0.0) 1 (4.3) 0 (0.0) 0 (0.0)
  1. aAll patients receiving fingolimod 1.25 mg/day were switched to fingolimod 0.5 mg/day after the fingolimod 1.25 mg/day dose was discontinued from all multiple sclerosis clinical studies.
  2. bAdverse events reported in 5% of patients or more in any treatment group during the extension phase.
  3. cThis single case of leukoencephalopathy was not of the type associated with progressive multifocal leukoencephalopathy.
Back to article page